We are a start-up company from Tohoku University that was newly listed on the Mothers Market at the Tokyo Stock Exchange (currently the Growth Market) on September 24, 2021. We research and develop various modalities (pharmaceuticals, medical devices, and program medical devices using artificial intelligence) to solve problems in the medical field, and contribute to the medical innovation, in order to create new medical care that allows patients to enjoy health both physically and mentally throughout their lives. Specifically, we are engaged in research and development and business to solve socially important medical issues, such as aging-related diseases (cancer, lung diseases) and women's and children's diseases. We are conducting research and development that connects treatment concepts and medical seeds across many medical departments conceived at universities and other research institutions in Japan and abroad, from basic research to clinical development (investigator-led clinical trials).

In the future, in addition to further promoting our existing pipelines, we are also considering challenging new areas such as longevity research. Through the promotion of these businesses, we will provide new medical value to society and steadily earn revenue in return, thereby growing into a company that can be sustained in the future. We aim to maximize value for all stakeholders who support our company and contribute to the development of society.

Chairman and CEO
Toshio Miyata